LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

By L. Ozelius, G. Senthil, R. Saunders-Pullman, E. Ohmann, Amanda Deligtisch, M. Tagliati, A. Hunt, Christine Klein, B. Henick, S. Hailpern and 4 more. New England Journal of Medicine, 2006

707 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology

View Paper: https://www.semanticscholar.org/paper/7ca9ae0e0c949c60378652e6d5553eacb247eb29

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Valina L. Dawson
2. T. Dawson
3. W. Ying

In Neurology

1. Valina L. Dawson
2. T. Dawson
3. H. Ko
4. Mark P. Mattson
5. D. Selkoe

Citations in the corpus

• Genetics of Parkinson's disease. (2012, background): “Mutations in the LRRK2 gene are the most frequent known cause of late-onset autosomaldominant and sporadic PD, with a mutation frequency ranging from 2% to 40% in different populations (Brice 2005; Lesage et al. 2006; Ozelius et al. 2006).”
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence (2011, background): “The frequency of the most common mutation, G2019S, varies across populations, is most common in North African and Jewish populations [210, 213], while it seems to be rare in Asian [214, 215] and South African populations [216].”
• Parkinson's disease: from monogenic forms to genetic susceptibility factors. (2009, background): “The penetrance of G2019S-associated disease increased from 17% at age 50 to 85% at age 70 in an initial family-based study (68), but varied in subsequent reports, depending on sample size, study design (case–control or family-based methods), inclusion of probands in the analysis, methods of calculat”
• Diagnosis and treatment of Parkinson disease: molecules to medicine. (2006, background): “With the discovery that mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are more common than expected in certain populations (37, 38), there is little doubt that screening patients at risk will become increasingly common.”
• Parkinson's disease: genetics and pathogenesis. (2011, background): “We now recognize that in cohorts of Ashkenazi Jewish PD patients, approximately 20% have GBA mutations (91, 92) and at least 15% have LRRK2 mutations (68, 71).”